IC8

IC8 is a specialized ionizable cationic lipid developed for advanced drug delivery systems, particularly lipid nanoparticle formulations for mRNA therapeutics. As a synthetic lipid, IC8 possesses a molecular formula of either C66H136N4O4 or C68H138M2O4 depending on the specific synthetic variant, with a molecular weight of approximately 1049.8 g/mol. The lipid remains stable when stored at –20°C and is slightly soluble in DMF and DMSO. Research has demonstrated that IC8 can be combined with other lipids to form LNPs that successfully deliver SARS‑CoV‑2 spike glycoprotein mRNA, inducing robust IgG responses against Delta and Omicron variants in murine models. Furthermore, IC8-containing LNPs have been employed to deliver mRNA encoding B7‑H3 × CD3 bispecific T cell engaging (BiTE) antibodies, achieving significant tumor growth reduction in MV4‑11 and A375 mouse xenograft models. As a research‑grade lipid, IC8 is supplied exclusively for laboratory and preclinical applications.

Product Parameters

Why Cosperpharm?

Cosperpharm is dedicated to advancing next‑generation drug delivery technologies by providing high‑purity ionizable lipids that meet the rigorous demands of preclinical research and process development. When your LNP formulation requires consistent, well‑characterized lipid components, Cosperpharm delivers IC8 with complete analytical traceability and documentation support. Each batch undergoes purity verification via HPLC (≥95%), with optional full‑batch characterization reports available upon request. Our responsive supply chain handles research‑scale quantities (mg to grams) with typical lead times of 5–7 business days. For customers integrating IC8 into GMP‑track development programs, Cosperpharm offers stability summaries, custom packaging, and technical consultation on LNP formulation parameters. With a global network serving academic institutions, biotechnology companies, and pharmaceutical manufacturers, Cosperpharm combines competitive pricing with transparent logistics — no hidden fees, no unexpected delays.

Product Advantages

1. Ionizable Cationic Lipid for Advanced mRNA Delivery

IC8 is specifically engineered as an ionizable cationic lipid, a critical component class for lipid nanoparticle formulations. Unlike permanent cationic lipids that can cause significant cytotoxicity, IC8 remains charge‑neutral at physiological pH (minimizing off‑target interactions and toxicity), while becoming protonated in the acidic endosomal environment to trigger membrane destabilization and efficient cytosolic release of nucleic acid cargo.

2. Proven In Vivo Efficacy Across Therapeutic Models

Published research confirms that IC8-based LNPs effectively deliver mRNA encoding viral antigens and bispecific T cell engagers, achieving measurable immune responses and anti‑tumor activity in animal models. Immunization with SARS‑CoV‑2 spike mRNA encapsulated in IC8-containing LNPs induced IgG responses against both Delta and Omicron variants. In oncology applications, IC8 LNPs delivering BiTE antibody mRNA reduced tumor growth in two separate xenograft models (MV4‑11 and A375).

3. Flexible Handling and Storage

IC8 is supplied as a stable solid that can be conveniently weighed and formulated. The lipid exhibits slight solubility in DMF and DMSO, enabling straightforward stock solution preparation for LNP formulation workflows. Storage at –20°C under recommended conditions preserves product integrity for extended periods.

4. Dual Application: LNP Formulation and Process Development

Beyond direct use in LNP formulation for research applications, IC8 serves as a valuable tool for process development scientists optimizing ionizable lipid synthesis, purification, and formulation parameters. The well‑characterized physical and chemical properties of IC8 support reproducible scale‑up from benchtop to preclinical batches.

FAQ

Q1: What is IC8?

A: IC8 is an ionizable cationic lipid used in the formulation of lipid nanoparticles for mRNA delivery. The compound has been demonstrated to deliver SARS‑CoV‑2 spike mRNA and BiTE antibody mRNA in preclinical models.

Q2:How should IC8 be stored?

A: Store IC8 at –20°C in a tightly sealed container, protected from light. Stock solutions in DMSO can be stored at –20°C for up to 1 month or at –80°C for up to 6 months.

Contact Us

From academic discovery projects to preclinical development programs, Cosperpharm delivers IC8 with the quality and reliability your research demands. Ready to move forward? Reach out to our team — we will respond within 24 hours with pricing, availability, and technical documentation tailored to your application.